Dr. Joe Yeong’s key research focus is to understand the resistance of cancer immunotherapy. He is the pioneer and key opinion leader in automation of quantitative multiplex (fluorescence-) immunohistochemistry (m-IHC/IF), utilising clinical autostainers to study and quantitate tumour immune microenvironment. He has established an integrative m-IHC/IF pathology platform in the Department of Anatomical Pathology, SGH which is the first of its kind in Asia-Pacific (APAC) region; providing a one-stop solution for scientists, clinicians, immunologists and pathologists to synergise their expertise in biomarker discovery and translation for clinical practice.


Principal Associate, Cancer Science Institute
Group Leader, Institute of Molecular and Cell Biology, A*STAR
Research Pathologist, Singapore General Hospital, Dept. of Anatomical Pathology
Visiting Associate Professor, Dept. of Surgery, Faculty of Medicine, University of Malaya
Visiting Fellow,Western Sydney University, Dept. of Pathology, Liverpool Hospital

Year(s) Degree (if applicable) Institute
2019 Master of Medicine (Pathology) University of Western Sydney
2016 Associateship Royal College of Pathologist (British)
2014 PhD (Cancer Immunology, Integrative
Science & Engineering)
National University of Singapore
2009 Bachelor of Medicine, Bachelor of Surgery Fudan University

IEEE workshop on AI & VR in Medicine 2018
4th Multidisciplinary Lung Cancer Conference (MLCC) 2018
2018 SGH Advance in Quantitative Pathology with Multiplex IHC Conference
World Immunotherapy Council (WIC, SITC) member
Organiser of World Immunotherapy Council’s 3rd Young Investigator Symposium 2019 (Society for Immunotherapy of Cancer 2019)
International Mentorship Program World Conference on Lung Cancer 2020 (International Association For the Study of Lung Cancer)
SLAS Technology Editorial Board Member
Guest Editor of Frontier in Molecular Bioscience


  1. Integrative translational research to combine tumour immunology and pathology (immunopathology), focusing on application of immune markers in routine clinical practice for diagnosis and prognosis, with emphasis on immunotherapy and precision medicine.
  2. Studying the mechanism of immunotherapy (anti-PD-1/PD-L1) resistance.
  3. Automation, standardization and translation of tissue based diagnostic test (processing-imaging-analysis).

His key research focus is to understand the resistance of cancer immunotherapy such as anti-PD-1/PD-L1 treatment by studying the interaction and function of PD-L1 with other markers and immune cells. Besides, from the technical perspective his team also aim to simple tool/technique that can easily overcome the barrier of lab technologies in order to enable every diagnostic lab in the world to perform high-end evaluation and analysis — to deliver better clinical care. He has been recognized worldwide for automation, standardization and translation of tissue processing-imaging-analysis techniques to routine clinical diagnostic.

He is the pioneer and KOL in automation of quantitative multiplex (fluorescence-) immunohistochemistry (m-IHC), using clinical autostainers to study and quantitate tumour immune microenvironment in clinical samples. The integrative m-IHC pathology platform that he established in the Division of Pathology, Singapore General Hospital is the first of its kind in Asia-Pacific (APAC) region to provide a one-stop solution for scientists, clinicians, immunologists and pathologists to work together, not only to discover biomarkers, but also to translate the biomarkers to clinical practice. In the era of cancer immunotherapy, such platform perfectly showcases the importance of the emerging new branch of diagnostic pathology – immunopathology.

His works on breast cancer, liver cancer and colorectal cancer are included in multiple National Medical Research Council (NMRC) funded studies as well as pharmaceutical industry sponsored projects. He is a member of the British Royal College of Pathologist (associateship), United States and Canadian Academy of Pathology, Pathology Society of Great Britain and Ireland and Society for Immunotherapy of Cancer. His key vision is to bridge between immunologists and pathologists to better harness the advances of immunotherapy and further beyond. He is one of the winners of the Best Mentor award of NUS Wong Hock Boon Research Society in 2017 for his dedication to mentor medical student on translational research. He also served as a committee member in the World Immunotherapy Council (WIC) Society for Immunotherapy of Cancer (SITC) and is one of the organizers for its 2019 WIC Young Investigator Symposium in National Harbour, USA.

Selected Publications

1. Yeong J, Tan T, Chow ZL, et al: Multiplex Immunohistochemistry/Immunofluorescence (mIHC/IF) for PD-L1 Testing in Triple-Negative Breast Cancer: A Translational Assay Compared with Conventional IHC. Journal of Clinical Pathology. jclinpath-2019-206252, 2020

2. Tan C, Nerurkar S, Cai H, et al. Overview of Multiplex Immunohistochemistry/Immunofluorescence Techniques in the Era of Cancer Immunotherapy. Cancer Communication. (in press, correspondent author)

3. Wo YJ, Gan ASP, Lim X, Tay ISY, Lim S,  Lim JCT, Yeong J. The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy. Cells. 2019;9(1)

4. Yeong J*, Lai CPT*, Tan AS*, Ong CHC, Lee B, et al. Evaluation of Phospor-Histone H3 in Asian Triple-Negative Breast Cancer using Multiplex Immunofluorescence. Breast Cancer Research and Treatment. 2019 Aug JIF: 3.471.

5. Yeong J, Tan AS*, Lai CPT*, Ong CCH, Lee B, et al. The Role of KI-67 in Asian Triple Negative Breast Cancers: A Novel Combinatory Panel Approach. Virchows Arch. 2019 Aug JIF: 2.868.

6. Lam JH, Ng HHM, Lim CJ, Sim XN, Malavasi F, Li H, Loh JJH, Sabai K, Kim JK, Ong CCH, Loh T, Leow WQ, Choo SP, Toh HC, Lee SY, Chan CY, Chew V, Lim TS, Yeong J, Lim TKH. Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular Carcinoma. Front Immunol. 2019 Sep 4;10:2093 IF: 6.429

7. Yeong J, L Gole, et al. Prognostic Value of CD8 + PD-1+ Immune Infiltrates and PDCD1 Gene Expression in Triple Negative Breast Cancer. J Immunother Cancer. 2019 Feb 6;7(1):34. JIF: 8.374

8. Wee YTF, Alkaff SMF, Lim JCT, Loh JJH, Hilmy MH, Ong C, Nei WL, Jain A, Lim A, Takano A, Azhar R, Wan WK, Newell E, Yeong J, Lim TKH. An Integrated Automated Multispectral Imaging Technique that Simultaneously Detects and Quantitates Viral RNA and Immune Cell Protein Markers in Fixed Sections from Epstein-Barr Virus-Related Tumours. Ann Diagn Pathol. 2018 Dec;37:12-19. JIF: 1.633

9. Yeong J, Lim JCT, Lee B, Li H, Chia N, Ong CCH, et al. High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer. Front Immunol. 2018 May 30;9:1209. JIF: 6.429.

10. Yeong J, Jeffrey Lim*, Chunjye Lim, et al. An Automated Staining Protocol for Seven-Colour Immunofluorescence of Human Tissue Sections for Diagnostic and Prognostic Use. Pathology. 2018 Apr;50(3):333-341. JIF: 2.968